These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12154051)

  • 1. Rhodacyanine dye MKT-077 inhibits in vitro telomerase assay but has no detectable effects on telomerase activity in vivo.
    Wadhwa R; Colgin L; Yaguchi T; Taira K; Reddel RR; Kaul SC
    Cancer Res; 2002 Aug; 62(15):4434-8. PubMed ID: 12154051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function.
    Wadhwa R; Sugihara T; Yoshida A; Nomura H; Reddel RR; Simpson R; Maruta H; Kaul SC
    Cancer Res; 2000 Dec; 60(24):6818-21. PubMed ID: 11156371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of ras-induced cancers by the F-actin-bundling drug MKT-077.
    Tikoo A; Shakri R; Connolly L; Hirokawa Y; Shishido T; Bowers B; Ye LH; Kohama K; Simpson RJ; Maruta H
    Cancer J; 2000; 6(3):162-8. PubMed ID: 10882332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation.
    Koya K; Li Y; Wang H; Ukai T; Tatsuta N; Kawakami M; Shishido ; Chen LB
    Cancer Res; 1996 Feb; 56(3):538-43. PubMed ID: 8564968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity.
    Pilzer D; Saar M; Koya K; Fishelson Z
    Int J Cancer; 2010 Mar; 126(6):1428-35. PubMed ID: 19739077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in mortalin level by its antisense expression causes senescence-like growth arrest in human immortalized cells.
    Wadhwa R; Takano S; Taira K; Kaul SC
    J Gene Med; 2004 Apr; 6(4):439-44. PubMed ID: 15079818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective damage to carcinoma mitochondria by the rhodacyanine MKT-077.
    Modica-Napolitano JS; Koya K; Weisberg E; Brunelli BT; Li Y; Chen LB
    Cancer Res; 1996 Feb; 56(3):544-50. PubMed ID: 8564969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortalin sensitizes human cancer cells to MKT-077-induced senescence.
    Deocaris CC; Widodo N; Shrestha BG; Kaur K; Ohtaka M; Yamasaki K; Kaul SC; Wadhwa R
    Cancer Lett; 2007 Jul; 252(2):259-69. PubMed ID: 17306926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of MKT 077, a rhodacyanine dye, against human tumor colony-forming units.
    Petit T; Izbicka E; Lawrence RA; Nalin C; Weitman SD; Von Hoff DD
    Anticancer Drugs; 1999 Mar; 10(3):309-15. PubMed ID: 10327038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photoactivation enhances the mitochondrial toxicity of the cationic rhodacyanine MKT-077.
    Modica-Napolitano JS; Brunelli BT; Koya K; Chen LB
    Cancer Res; 1998 Jan; 58(1):71-5. PubMed ID: 9426060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An N-terminal region of mot-2 binds to p53 in vitro.
    Kaul SC; Reddel RR; Mitsui Y; Wadhwa R
    Neoplasia; 2001; 3(2):110-4. PubMed ID: 11420746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
    Kelland LR
    Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inhibition of telomeres and telomerase. Seeking for new anticancer drugs].
    Raymond E; Faivre S; Dieras V; Von Hoff D
    Bull Cancer; 1997 Dec; 84(12):1123-33. PubMed ID: 9587365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Telomeres, telomerase and cancer].
    Soria JC; Rixe O
    Bull Cancer; 1997 Oct; 84(10):963-70. PubMed ID: 9435798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of mortalin to cancer cell stemness and cancer therapy.
    Yun CO; Bhargava P; Na Y; Lee JS; Ryu J; Kaul SC; Wadhwa R
    Sci Rep; 2017 Feb; 7():42016. PubMed ID: 28165047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomerase inhibitors in cancer therapy: current status and future directions.
    Incles CM; Schultes CM; Neidle S
    Curr Opin Investig Drugs; 2003 Jun; 4(6):675-85. PubMed ID: 12901225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomere biology of pediatric cancer.
    Tabori U; Dome JS
    Cancer Invest; 2007; 25(3):197-208. PubMed ID: 17530490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-RAS cancer drug MKT-077 is an F-actin cross-linker.
    Maruta H; Tikoo A; Shakri R; Shishido T
    Ann N Y Acad Sci; 1999; 886():283-4. PubMed ID: 10667240
    [No Abstract]   [Full Text] [Related]  

  • 19. Withanone binds to mortalin and abrogates mortalin-p53 complex: computational and experimental evidence.
    Grover A; Priyandoko D; Gao R; Shandilya A; Widodo N; Bisaria VS; Kaul SC; Wadhwa R; Sundar D
    Int J Biochem Cell Biol; 2012 Mar; 44(3):496-504. PubMed ID: 22155302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
    Tárkányi I; Aradi J
    Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.